Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world
Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology
IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced promising preclinical results for IGC-M3, a novel small molecule designed to address multiple biological drivers of Alzheimer's disease. IGC-M3 demonstrated activity in laboratory models against beta-amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation, four key contributors to Alzheimer's pathology.
The findings underscore IGC Pharma's dual-pronged strategy in Alzheimer's disease, which includes:
IGC-AD1 - A proprietary, cannabinoid-based formulation currently in Phase 2 clinical trials for agitation in Alzheimer's disease, with potential disease-modifying effects under investigation.
IGC-M3 - A multifunctional, next-generation small molecule with the potential to impact multiple disease mechanisms, currently in preclinical development.